Literature DB >> 3038010

In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.

M Walsh, E W Kappus, T C Quinn.   

Abstract

The antimicrobial activity of CP-62,993 against four Chlamydia trachomatis isolates was compared with those of erythromycin, clindamycin, and tetracycline. The MIC of CP-62,993 was 0.26 to 1.02 micrograms/ml for 100% inclusion inhibition and 0.031 to 0.063 microgram/ml for 50% inclusion inhibition. With pharmacokinetic and antimicrobial studies demonstrating prolonged half-life and in vitro effectiveness, CP-62,993 may make possible a single, short-course treatment regimen for C. trachomatis infection.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3038010      PMCID： PMC174839          DOI： 10.1128/AAC.31.5.811

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Antibiotic susceptibility of Chlamydia trachomatis.

Authors:  H J Blackman; C Yoneda; C R Dawson; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

Review 2.  Chlamydial infections (third of three parts).

Authors:  J Schachter
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

Review 3.  Epidemiology of sexually transmitted Chlamydia trachomatis infections.

Authors:  S E Thompson; A E Washington
Journal:  Epidemiol Rev       Date:  1983       Impact factor: 6.222

4.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

Review 5.  Treatment of sexually transmitted chlamydial infections.

Authors:  L L Sanders; H R Harrison; A E Washington
Journal:  JAMA       Date:  1986-04-04       Impact factor: 56.272

6.  The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients.

Authors:  S E Thompson; W D Hager; K H Wong; B Lopez; C Ramsey; S D Allen; M D Stargel; C Thornsberry; B B Benigno; J D Thompson; J A Shulman
Journal:  Am J Obstet Gynecol       Date:  1980-01-15       Impact factor: 8.661

7.  Detection of Chlamydia trachomatis inclusions in Mccoy cell cultures with fluorescein-conjugated monoclonal antibodies.

Authors:  W E Stamm; M Tam; M Koester; L Cles
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

8.  Microtest procedure for isolation of Chlamydia trachomatis.

Authors:  B L Yoder; W E Stamm; C M Koester; E R Alexander
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

9.  The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.

Authors:  G L Ridgway; J M Owen; J D Oriel
Journal:  Br J Vener Dis       Date:  1978-04
  9 in total
  21 in total

1.  In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  L E Welsh; C A Gaydos; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  An automated image-based method for rapid analysis of Chlamydia infection as a tool for screening antichlamydial agents.

Authors:  Ichie Osaka; Jeffrey M Hills; Sarah L Kieweg; Heather E Shinogle; David S Moore; P Scott Hefty
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

5.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

6.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

7.  Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells.

Authors:  D Raoult; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

8.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  A Agacfidan; J Moncada; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.